Platelet glycoprotein IIb/IIIa receptor blockade: lessening the risk of coronary interventions.
For the patient undergoing percutaneous coronary intervention, the administration of a platelet glycoprotein IIb/IIIa receptor blocker reduces the incidence of a periprocedural nonfatal myocardial infarction and the need for unplanned emergency stenting. In the diabetic patient undergoing intracoronary stenting, the use of a platelet glycoprotein IIb/IIIa receptor blocker appears to decrease the need for subsequent target vessel revascularization. There is considerable evidence in support of the use of glycoprotein IIb/IIIa receptor inhibitors in all categories of patients--"high-risk" patients, "low-risk" patients, and those undergoing primary angioplasty for acute myocardial infarction--and for the full armamentarium of percutaneous procedures (angioplasty, directional atherectomy, rotational atherectomy, and intracoronary stenting).
Pitts
W R
WR
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235-9047, USA.
Lange
R A
RA
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011183:Postoperative Complications / Q000517:prevention & control; D015607:Stents / Q000009:adverse effects
D005343:Fibrinolytic Agents; D019039:Platelet Glycoprotein GPIIb-IIIa Complex